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to the ability of therapeutic interventions to strictly control local joint inflammation?
Finally, how important is it in the clinical care of patients with RA that articular bone erosions heal? Strong evidence certainly exists for the correlation of bone erosion and joint damage with functional disability over time in these patients, but we do not yet know the functional implications of erosion repair. Nonetheless, if a direct correlation between local control of inflammation and repair of erosions were to be clearly estab lished in patients, then repair might become an important indicator of therapeutic effi cacy. The use of animal models of RA will be important to further elucidate the molecular pathways that are active at sites of erosion, and that create a local micro environment conducive for bone repair.
In summary, Finzel et al. 1 have clearly shown that repair of bone erosions can occur in patients with RA, and is character ized by formation of new bone at the base of deep erosions. Control of inflammation, which is likely to be key in shifting the balance towards bone formation and facilitating healing of erosions, remains an important clinical goal. 4 performed a validation study for a simple predictive model of 5year survival in patients with SSc, originally developed in 1999 by Bryan and colleagues. 5 In this commentary we discuss their results in the context of the specific challenges in develop ing and validating prognostic tools for use in SSc, which need to be considered before applying such instruments in the clinic, or when de veloping new predictive models.
Risk prediction rules enable clinicians to interpret medical data for diagnostic, therapeutic and prognostic assessment, by providing the probability of a par ticular outcome, such as 5year mortality. These prognostic models are developed by apply ing statistical techniques to identify com binations of predictor variables that cate gorize a group of patients with a spe cific disease into risk subgroups. Over the past 20 years, changes in healthcare systems and the advent of evidencebased medicine have forced increased attention on to the development of prediction rules that are simple to use, but which are also accurate and robust. The most wellknown example of a patient assessment tool that uses clini cal risk prediction rules is the Framingham Coronary Heart Disease Prediction Score. 6 Methodological standards for the develop ment of prediction rules were proposed by Wasson et al. 7 and were later modi fied by Laupacis and colleagues. 8 Further more, several publications have discussed the NATURE REVIEWS | RHEUMATOLOGY VOLUME 7 | NOVEMBER 2011 | 629
factors that are important for effective vali dation of prediction rules. 9, 10 Despite these solid methodological foundations, the iden tification of clinical features that predict mortality in patients with SSc has been dif ficult, primarily because individuals with the disease only represent a small percentage of the general population. Only a few investi gators from a small number of clinics have followed enough patients with SSc over time to enable robust estimation of the prognos tic value of clinical factors in relation to dis ease outcomes. For this reason, many of the published studies examining risk factors for mortality in SSc have used prevalent popula tions, as opposed to an inception cohort of newly presenting cases. This type of selec tion means that a study might not include patients who died early in the course of the disease, resulting in a population dis proportionately composed of patients with longstanding SSc. Underrepresentation of patients with early SScassociated fatality could result in failure to identify risk factors predictive of this outcome, and the resul tant model would fail to provide an accu rate prognosis when applied to patients in earlier stages of disease.
In their 1999 publication, 5 Bryan et al. described a simple tool for prediction of 5year mortality in patients with SSc on the basis of three clinical factors. The model was developed in a prospective cohort of 280 patients with SSc who were referred to a single center for evaluation upon dis ease onset (defined as the first demon stration of cutaneous symptoms) between 1982 and 1991. A minimum of 5 years of followup data were required for a patient to be included in the study. The prediction rules were developed using logistic regres sion followed by a Monte Carlo simulation method. In addition to age and gender, sig nificant predictors of mortality included an erythro cyte sedimentation rate (ESR) elevated to ≥25 mm/h, proteinuria above trace, and a lung carbon monoxide diffus ing capacity (DLCO) <70% of the predicted value. The presence of all three clinical risk factors was found to predict 100% mortality at 5 years. This model is appealing owing to its simplicity, but had not been externally validated in another population of patients with SSc; external validation of this predic tion model was the purpose of the study by Fransen and coworkers. 4 When applied to external validation cohorts, the performance of prediction rules is frequently disappointing, for three main reasons. Firstly, the patient populations included in the development and validation cohorts might differ in their clinical com position. This can have an effect on both discrimination (the ability of the risk pre diction rules to distinguish those patients who will or will not die at the specified time point) and calibration (the degree of similarity between observed and predicted risks) of the model. Clinical variables in populations of patients with SSc that could affect the performance of the model include disease duration (as discussed above), and the proportion of patients with diffuse versus limited cutaneous SSc. These two subsets of the disease have different clini cal features and natural history, with mul tiple published studies confirming worse survival in diffuse SSc. Secondly, the defi nitions of the predictor variables, or the techniques used to measure them, might differ between the development and valida tion cohorts. Finally, validation cohorts are often smaller than development cohorts, which will decrease the power and accuracy of any statistical analyses.
The validation cohort in the study by Fransen and colleagues 4 was a European multicenter population of patients with SSc, diagnosed before 2002, with followup for at least 5 years or until death. Centers from the European League against Rheumatism Scleroderma Trials and Research (EUSTAR) group were invited to enroll patients. The authors examined the predictor variables (presence of urine protein, elevated ESR and low DLCO) originally proposed by Bryan et al. 5 to evaluate their power of discrimi nation. These variables were assessed by chart review and medical corres pondence, and then electronically transferred to the research center. A total of 1,049 patients were included in the analysis, and thus small sample size was not a limitation of the study. Any missing data for variables were replaced by single imputation, after which no bias was observed between patients who lived and those who died. The discrimi nation of the prediction rules was accept able, with an area under the curve (AUC) for the original model of 0.78 (95% CI 0.74-0.82). The authors also recalibrated the model using the regres sion coeffi cients obtained from their multi variable model, and included disease subset as an additional variable (diffuse versus limited), which only resulted in a slight improvement in the AUC to 0.81 (95% CI 0.78-0.85).
The observed mortality was only 31% among the patients presenting with all three risk factors in the validation cohort, 4 suggest ing a major overestimation of death at 5 years by the original model (predicted mortality of 100%). Thus, in this validation cohort, the model showed good discriminatory perfor mance but considerable overestimation and, hence, poor calibration, limiting its potential clinical use. This variation could, in part, be attributable to the validation cohort being enrolled one decade later, during which time therapeutic regimens have changed and might have improved survival. Another contributor is that the validation cohort had more patients with limited cutaneous SSc, and also comprised a prevalent population that is more likely to have included patients with a longer disease duration before enroll ment (average disease duration was not reported), compared with the development cohort. These findings demonstrate, as pointed out by Fransen et al., 4 that testing of prediction models in the appropriate clinical context in which they were developed is of vital importance.
The factors discussed above represent considerable challenges for the develop ment and validation of clinical risk predic tion rules in patients with SSc. The proper use of the many national and international registries of patients with SSc that have been established will be beneficial for the future understanding of mortality in this disease. Collaboration and planning between these centers as well as consideration of separate models for diffuse and limited cutaneous SSc will be vital in the development and validation of risk stratification tools in SSc. Accurate predictor variables, ultimately incorporating serologic, genetic and bio marker information, can then be applied to patient care and clinical trial design. 
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